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Major reductions in death rates in acute coronary syndromes (ACS) 
were achieved with the implementation of percutaneous coronary
intervention allowing rapid coronary reperfusion.1 Nonetheless,
mortality and morbidity remain substantial during the ensuing five 
years after an acute coronary syndrome (ACS).2 Indeed, between 1987
and 2006, survival among 30-day survivors of ACS has not improved
despite a marked reduction in early mortality and a substantial shift 
in the epidemiology of MI with the introduction of cardiac troponins in
laboratory diagnostic tests.3 Thus, improvements in early diagnosis, risk
stratification and clinical management of patients presenting with ACS
are needed. ACS comprises the distinct entities of unstable angina 
(UA), non-ST elevation myocardial infarction (NSTEMI) and ST elevation
myocardial infarction (STEMI), as defined by the current European
Society of Cardiology (ESC) and American Heart Association/American
College of Cardiology (AHA/ACC) guidelines.4–6 Among the tools available
for diagnosis, risk stratification, and clinical management of ACS,
biomarkers figure prominently.7 Troponins as specific markers of
myocardial necrosis constitute the main circulating biomarker for the
differentiation between UA and NSTEMI,6 and an early invasive strategy
in high-risk patients identified by elevated troponin levels is associated
with better short- and long-term outcomes.8
The development of novel high-sensitivity cardiac troponin (hs-cTn) assays
for the quantification of cardiac troponins in the circulation at plasma
concentrations at the 99th percentile or lower in a reference population
with a coefficient of variance of ≤10  % made it possible to fulfil the 
quality criteria postulated by the Joint ESC/ACCF (American College of 
Cardiology Foundation)/AHA/WHF (World Heart Federation) Task Force 
for the Redefinition of Myocardial Infarction.6 In addition to determining 
the absolute plasma concentrations of cardiac troponins, the rise or fall of
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cardiac troponin (cTn) levels constitutes an important means to differentiate
patients with mild, but relevant, troponin elevations in ACS from those with
chronically elevated baseline levels; for example, in stable coronary heart
disease.6 Figure 1 shows the distinct scenarios based on elevated absolute
concentration and/or a concomitant rise and fall of troponins over time.
Detecting Patients at Elevated Risk and with
Subclinical Disease
Cardiac troponin levels detectable by the novel hs-cTn assays are up to
10-fold lower than those detected by the conventional cTn assays.9 Thus,
the lower limit of detection of the new high-sensitivity troponin T (hs-TnT)
assay by Roche (Elecsys Troponin T®, Roche Diagnostics, Mannheim,
Germany) is 0.003 μg/l compared with 0.01 μg/l for the conventional
fourth-generation assay corresponding to 0.03 μg/l for the high-sensitivity
cardiac troponin T (hs-cTnT) assay.9
Of note, three large population-based cohort studies in apparently
healthy individuals using the same hs-cTnT assay showed detectable
cardiac troponin T (cTnT) concentrations in a substantial proportion of
subjects: 25 % in the Cardiovascular health study,10 66 % in the Dallas
heart study,11 and 66.5  % in the Atherosclerosis risk in communities
(ARIC) study.12 Importantly, elevated hs-TnT levels were also associated
with increased mortality in all three studies. 
Among those three studies, the ARIC study had the strongest association
of hs-cTnT levels with fatal coronary events (odds ratio [OR] 7.59, 95 %
confidence interval [CI] 3.78–15.25), hospitalization for congestive heart
failure (OR 5.95, 95 % CI 4.47–7.92) and overall mortality (OR 3.96, 95 % CI
3.21–4.88), but weaker associations with non-fatal coronary events and
coronary revascularizations (OR 2.29, 95  % CI 1.81–2.89). This may
indicate that elevated high-sensitivity troponin (hs-Tn) levels primarily
predict structural heart disease events rather than atherothrombotic
events. Indeed, conflicting evidence exists as to whether stress-induced
ischemia is associated with detectable troponin levels using hs-cTn
assays.13,14 Beyond silent ischemia, coronary microvascular dysfunction,
structural and functional myocardial alterations as well as apoptosis 
may account for troponin release from cardiac myocytes. In patients at
high risk of cardiovascular events, such as those with congestive heart
failure15 or stable coronary artery disease,9 troponin T levels detectable
with the high-sensitivity assay but not with the fourth-generation
conventional assay were independently associated with adverse
cardiovascular outcomes, but not with non-fatal coronary events.
Diagnosis of Patients with Acute 
Coronary Syndrome
For STEMI, an electrocardiogram (ECG) provides enough information for
decision-making, but the distinction between NSTEMI and UA or non-cardiac
chest pain requires sensitive and specific biomarkers. Although troponins
outweigh other markers of myocardial necrosis in several aspects,
conventional cTn tests are disadvantageous in that they can detect a rise 
in circulating troponin plasma concentration only three to four hours after
myocardial damage occurs – similar to creatine kinase myocardial band 
(CK-MB). Previously, optimal sensitivity of conventional cTn tests could only
be achieved six or even nine hours after the onset of myocardial necrosis.6
Therefore, conventional cTn tests provide an insufficient sensitivity to
exclude (‘rule out’) AMI (i.e., NSTEMI) in the immediate phase after the onset
of chest pain. Accordingly, previous joint guidelines of the AHA and National
Academy of Clinical Biochemists recommended the retest of troponin levels
in ‘troponin-negative’ NSTEMI patients for at least six hours.16
This gap can now be narrowed by the use of novel hs-Tn assays. Owing
to the improved sensitivity (∼70 % with cTn assays and ∼90 % with novel
Figure 1: Kinetics of Cardiac Troponin and Detection by
Conventional and by High-sensitivity Cardiac Troponin
Assays in Patients with Acute Coronary Syndromes
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The figure shows distinct scenarios combining measurements of troponin levels by conventional
cardiac troponin (cTn) assays and by high-sensitivity cardiac troponin (hs-cTn) assays, based 
on the criteria of an elevated value (beyond the cut-off is shown in pink for cTn, and blue and
pink for hs-cTn) and a concomitant rise and/or fall over time. The red line shows a typical
example of a patient with an evolving acute myocardial infarction (AMI) and the green line
shows a clear-cut negative result that rules out AMI. The violet line shows an example of a
patient who should be classified as AMI based on the hs-cTn assay, which, in turn, would go
unnoticed on cTn assays. The blue line constitutes a typical example of a patient with a distinct
etiology of elevated troponin level other than AMI, as the criterion of a rise/fall is not fulfilled.
Figure 2: European Society of Cardiology Guidelines 
for Ruling out Acute Coronary Syndromes Using 
High-sensitivity Cardiac Troponin Assays
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This algorithm proposed in the European Society of Cardiology guidelines summarizes the
current evidence and provides a practical tool for patient management.
cTn = cardiac troponin; Δ = delta criterion (changes over time); GRACE = Global 
Registry of Acute Coronary Event risk score; hs-cTn = high-sensitivity cardiac troponin; 
PCI = percutaneous coronary intervention; ULN = upper limit of normal.
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hs-cTn assays), a higher negative predictive value is established with a
negative hs-cTn test result.17,18 As a consequence, the most recent ESC
guidelines for the diagnosis of ACS reduce the time interval for retesting
in initially hs-cTn-negative ACS patients to three hours4 (see Figure 2). 
However, as a trade-off, the increase in sensitivity is accompanied by a
diminished specificity for MI (97 % with cTn assays and 91 % with novel 
hs-cTn assays) and a reduced positive predictive value (85  % with cTn
assays and 77  % with novel hs-cTn assays).17,18 Interestingly, in the ARIC
population study, 7.4 % of individuals had cTnT levels ≥0.0014 μg/l—the
current threshold level for acute MI (AMI) issued by the manufacturer—and
the 99th percentile value was substantially higher at 0.03 μg/l,12 calling into
question the versatility of a single cut-off across different ages, gender and
renal function. In fact, the diagnostic performance of hs-cTn assays varies
substantially in elderly patients, with a suspicion of ACS effecting distinct
receiver operating characteristic (ROC)-derived cut-offs.19
The expected decrease in specificity and positive predictive value was
recently substantiated by a study in chest pain patients presenting to
the accident and emergency (A&E) department that showed a reduced
Figure 3: Global Registry of Acute Coronary Event Risk Score in Patients with Acute Coronary Syndromes for 
All-cause Mortality from Discharge to Six Months
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The figure shows the various parameters, including conventional cardiac troponin, that make the Global Registry of Acute Coronary Event (GRACE) risk score. Adapted from Eagle, et al., 2004.32
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positive predictive value (38 %) for the hs-cTnT test compared with the
conventional cTnT test (67–72 %).20
These findings underline the futility of using an absolute threshold 
level alone and strongly call for additional parameters, such as the kinetics
of troponin levels and/or additional biomarkers, for making the diagnosis of
MI. Indeed, the former was addressed by a study showing that a doubling
of the hs-cTnT concentration within three hours of the first time-point in
conjunction with initially elevated hs-TnT levels allowed an increase in the
positive predictive value for AMI to 100  %.21 Serial testing using hs-Tn
assays at zero and six hours after hospitalization increases both sensitivity
and specificity, and implementation of a delta criterion (% increase) further
enhances specificity.22 Absolute changes of cTn levels determined two
hours apart have a significantly higher diagnostic accuracy for AMI than
relative changes (area under the ROC curve [AUC] for hs-TnT 0.95 versus
0.76; cardiac troponin I ultra 0.95 versus 0.72).23
Three recent studies analysed the combination of copeptin (the
arginine–vasopressin prohormone-derived peptide) in conjunction with
hs-cTn for the rapid rule-out of MI. The use of pre-specified cut-offs for
both markers was associated with an improvement in the rule-out of MI
in patients admitted to the A&E department with a likely diagnosis of
NSTEMI,24 whereas in patients presenting with acute chest pain, initial
negative conventional cTnT levels and a non-diagnostic ECG, the rapid
rule-out of MI using hs-TnT could not be further enhanced by adding
copeptin (continuous) levels.25 For the identification of patients with MI
presenting within three hours of onset of chest pain, a high-sensitivity
cardiac troponin I (hs-cTnI) assay delivered an AUC of 0.96 alone, with a
small but significant improvement to an AUC of 0.97 (p=0.00397) when
copeptin was added.26 In all studies, the specificities remained low.
Risk Stratification of Patients with 
Acute Coronary Syndrome
The risk stratification of patients with ACS is of paramount clinical
importance. Most, but not all, studies that simply compared
conventional and sensitive troponin assays found that sensitive
troponin assays improve risk prediction of event-free survival at both 
30 days and one year.22,27–29 However, the predictive value of sensitive
troponin assays must be regarded in conjunction with risk scores that
combine the clinical parameters, ECG findings and basic laboratory
parameters that have a well-documented clinical value and are
recommended by current guidelines.4,5
Commonly used is the Thrombolysis in Myocardial Infarction (TIMI) risk
score, based on the series of TIMI studies for patients with UA/NSTEMI30
(see Table 1) and STEMI,31 respectively. In turn, the Global Registry 
of Acute Coronary Event (GRACE) risk score (see Figure 3) is based 
on registry data and was developed to comprise all ACS entities.32
Clinical risk scores (all of which contain conventional troponin 
plasma concentration) provide the backbone against which novel
biomarkers need to show incremental benefit as assessed by statistical
methods using c-statistics, integrated discriminating index and net
reclassification improvement (NRI). High-sensitivity troponin assays 
did not improve risk prediction in studies that included both STEMI and
NSTEMI patients.33,34 In patients with acute chest pain,6 high-sensitivity
troponin assays improved the prediction of death, but not of subsequent
AMI, with an improved reclassification of patients (NRI 0.91) after
adjustment for the TIMI risk score.34
A recent multimarker analysis in the MERLIN-TIMI 36 trial of 4,352 patients
with NSTEMI, identified a hs-cTn net improvement over the clinical TIMI 
risk score (excluding troponin) with c-index 0.784 ≥ 0.805 (p=0.005) and 
NRI 0.389 (p<0.001) for cardiovascular death and similarly for MI,
hospitalization for congestive heart failure and the composite endpoint 
of cardiovascular death and hospitalization for congestive heart failure.35
Furthermore, patients presenting with ACS and reclassified into NSTEMI
from UA based on hs-Tn against cTn testing correlated with an increased
Acute Coronary Syndromes
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Table 1: Thrombolysis in Myocardial Infarction Risk Score
for Patients with Unstable Angina and Non-ST-elevation
Myocardial Infarction – Predictor Variables
Predictor Point Value Definition
Variable of Variable
Age ≥65 1
years
≥3 risk 1 Risk factors:
factors for • Family history of CAD
CAD • Hypertension
• Hypercholesterolemia
• Diabetes
• Current smoker
Aspirin use 1
in last 7 days
Recent, 1 ≥2 anginal events in last 24 hours
severe
symptoms 
of angina
Elevated 1 CK-MB or cardiac-specific troponin level
cardiac
markers
ST deviation 1 ST depression >0.5 mm is significant;
≥0.5 mm transient ST elevation >0.5 mm for 
<20 minutes is treated as ST-segment
depression and is high risk; ST elevation
>1 mm for >20 minutes places patients in the
STEMI treatment category
Prior 1 Risk predictor remains valid even if this
coronary information is unknown
artery
stenosis
>50 %
Calculated Risk of ≥1 Risk Status
TIMI Risk Primary
Score Endpoint*
in ≤14 days
0 or 1 5 % Low
2 8 % Low
3 13 % Intermediate
4 20 % Intermediate
5 26 % High
* Primary endpoints: death, new or recurrent MI or need for 
urgent revascularization
CAD = coronary artery disease; CK-MB = creatine kinase myocardial band; 
MI = myocardial infarction; (N)STEMI = (non-)ST-elevation myocardial infarction; 
TIMI risk score = Thrombolysis in Myocardial Infarction risk score. 
Adapted from Antman, et al., 2000.30
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risk of major adverse cardiovascular events and significantly improved risk
stratification.27,36 In conclusion, if combined with clinical scores, sensitive
troponin assays appear to improve risk prediction in NSTEMI–ACS patients
but not, or less so, in STEMI patients.
Clinical Management of Patients with 
Acute Coronary Syndromes
As of now, only scarce data exist on the effect of introducing hs-Tn
assays into clinical practice with respect to clinical management and
outcomes after therapeutic intervention. Interestingly, lowering the
diagnostic threshold of cardiac troponin I (cTnI) from 0.20 ng/l to
0.05 ng/l by the introduction of a sensitive troponin assay (1,038 patients
before and 1,054 after implementation) not only increased the rate of
NSTEMI diagnosed in patients with suspected ACS, but also translated
into major reductions in morbidity and mortality.37 Future trials will need
to examine the benefit of an invasive therapy in AMI patients with
elevated troponin, similar to those of the previous era with conventional
cTn.38 A prerequisite is the exploration of quantitative cut-offs for hs-Tn
and changes over time (delta criterion) to serve as a guidance for
therapeutic interventions.
Summary and Conclusions
The availability of hs-cTn tests has improved the diagnostics of 
patients presenting to the A&E department with chest pain.
Nonetheless, clinical judgement has become evermore important for
the correct interpretation of test results that integrate both laboratory
parameters (absolute values of hs-Tn and the kinetics thereof) 
with clinical symptoms and ECG signs of myocardial ischemia to 
make the diagnosis of AMI. The increase in sensitivity of hs-cTn tests 
at the expense of diminished specificity constitutes a challenge to 
make the diagnosis (‘rule-in’) of AMI. This important topic is currently
addressed in two ways: 
•   by analyzing the absolute/relative increase in hs-Tn concentration
over the time necessary to make the diagnosis of AMI; and 
•   by combining the hs-Tn test with an ideally disease-specific
complementary biomarker to enable the diagnosis of AMI at a single
time-point. 
Evidence is accumulating that hs-cTn assays improve short- and 
long-term prediction, at least in NSTEMI patients, beyond clinical risk
prediction rules, which include cTn levels measured by conventional
assays. In addition, beyond risk estimation for elevated hs-cTn
concentration, the role of hs-cTn testing in the choice of therapeutic
intervention and its effects on clinical outcomes are being analysed.
Finally, the underlying mechanism for the stronger association of
elevated troponin levels with structural heart disease events rather
than with atherothrombotic events is of major interest. n
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